Acthar and MS
Acthar delivers proven relief of MS relapses
- Acthar effectively accelerates recovery based on improvements in patients' disability scores
- In multiple head-to-head clinical studies, there were no demonstrated differences between the efficacy and safety of IV steroids and ACTH[3-5]
*Results from a double-blind, randomized, controlled study investigating disability outcome (Kurtzke Disability Status Scale) in patients with acute MS relapse before, during, and after treatment with IVMP and intramuscular ACTH. The IVMP group (n=29) received 1 gram daily for 3 days. The ACTH group (n=32) received 80 units daily for 7 days, 40 units daily for 4 days, and 20 units daily for 3 days.
†Compared efficacy with IVMP. No demonstrated difference was found between the 2 groups in either the rate of recovery or in the final outcome for acute relapse at 12 weeks (n=32, ACTH; n=29, IVMP).
§Compared therapeutic efficacy with dexamethasone and IVMP (n=10, ACTH; n=10, IVMP; n=10, dexamethasone). No significant difference was found between IVMP and ACTH at days 7 and 30.
‡Compared clinical response to IVMP. No significant difference was found between the 2 groups at 3 months (n=11,ACTH; n=14, IVMP).
The exact chemical form of ACTH used in these studies is unknown